Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer

European Journal of Cancer

Volumn 50, Issue 15, 2014, Pages 2592-2601

  Van Der Burg, M E L ^a   Onstenk, W ^a   Boere, I A ^a   Look, M ^a   Ottevanger, P B ^b   De Gooyer, D ^c   Kerkhofs, L G M ^d   Valster, F A A ^e   Ruit, J B ^f   Van Reisen, A G P M ^g   Goey, S H ^h   Van Der Torren, A M E ⁱ   Ten Bokkel Huinink, D ^j   Kok, T C ^k   Verweij, J ^a   Van Doorn, H C ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Franciscus Hospital   (Netherlands)

^d Admiraal De Ruyter Hospital   (Netherlands)

^e Lievensberg Hospital   (Netherlands)

^f Vlietland Hospital   (Netherlands)

^g Department of Internal Medicine ZorgSaam Zeeuws Vlaanderen ^*  (Netherlands)

^h Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

ⁱ GROENE HART HOSPITAL   (Netherlands)

^j DEPARTMENT OF SURGERY   (Netherlands)

^k Maasstad Hospital   (Netherlands)

more..

Author keywords

Carboplatin; Cisplatin; Dose dense; Epithelial ovarian cancer; First line; Paclitaxel; Weekly

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADULT; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; EUROPE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEUTROPENIA; OVARIAN NEOPLASMS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; VERY ELDERLY; VOMITING; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EUROPE; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; MIDDLE AGED; NAUSEA; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEUTROPENIA; OVARIAN NEOPLASMS; PACLITAXEL; TIME FACTORS; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 84907435577     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.07.015     Document Type: Article

References (33)

1. A. du Bois, H.J. Luck, W. Meier, H.P. Adams, V. Mobus, and S. Costa A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 17 2003 1320 1329
2. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1 1996 1 6
3. J.P. Neijt, S.A. Engelholm, M.K. Tuxen, P.G. Sorensen, M. Hansen, and C. Sessa Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer J Clin Oncol 18 17 2000 3084 3092
4. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study J Clin Oncol 21 17 2003 3194 3200
5. M.J. Piccart, K. Bertelsen, G. Stuart, J. Cassidy, C. Mangioni, and E. Simonsen Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gynecol Cancer 13 Suppl. 2 2003 144 148
6. M.A. Bookman, M.F. Brady, W.P. McGuire, P.G. Harper, D.S. Alberts, and M. Friedlander Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup J Clin Oncol 27 9 2009 1419 1425
7. A. du Bois, J. Herrstedt, A.C. Hardy-Bessard, H.H. Muller, P. Harter, and G. Kristensen Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer J Clin Oncol 28 27 2010 4162 4169
8. A. du Bois, B. Weber, J. Rochon, W. Meier, A. Goupil, and S. Olbricht Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens J Clin Oncol 24 7 2006 1127 1135
9. P. Hoskins, I. Vergote, A. Cervantes, D. Tu, G. Stuart, and P. Zola Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel J Natl Cancer Inst 102 20 2010 1547 1556
10. K. Lindemann, R.D. Christensen, I. Vergote, G. Stuart, M.A. Izquierdo, and J. Kaern First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC) - a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG Ann Oncol 23 10 2012 2613 2619
11. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, and H. Huang Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 26 2011 2473 2483
12. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, and G. Kristensen A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 26 2011 2484 2496
13. F.E. de Jongh, R. de Wit, J. Verweij, A. Sparreboom, M.J. van den Bent, and G. Stoter Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer Eur J Cancer 38 15 2002 2005 2013
14. H. Gelderblom, A. Sparreboom, M.J. de Jonge, W.J. Loos, E. Wilms, and M.A. Mantel Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer Br J Cancer 85 8 2001 1124 1129
15. M.E. van der Burg, R. de Wit, W.L. van Putten, A. Logmans, W.H. Kruit, and G. Stoter Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer Br J Cancer 86 1 2002 19 25
16. M.E. van der Burg, I. Vergote, W. Onstenk, I.A. Boere, K. Leunen, and C.A. van Montfort Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer Eur J Cancer 49 6 2013 1254 1263
17. E. Pujade-Lauraine, U. Wagner, E. Aavall-Lundqvist, V. Gebski, M. Heywood, and P.A. Vasey Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse J Clin Oncol 28 20 2010 3323 3329
18. N. Katsumata, M. Yasuda, F. Takahashi, S. Isonishi, T. Jobo, and D. Aoki Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Lancet 374 9698 2009 1331 1338
19. N. Katsumata, M. Yasuda, S. Isonishi, F. Takahashi, H. Michimae, and E. Kimura Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial Lancet Oncol 14 10 2013 1020 1026
20. S. Pignata, G. Scambia, D. Katsaros, C. Gallo, E. Pujade-Lauraine, and S. De Placido Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial Lancet Oncol 15 4 2014 396 405
21. NCI. Common Toxicity Criteria CTC version 2.0. Cancer Therapy Evaluation Program 1999:35.
22. J. Chan, M. Brady, R.T. Penson, B.J. Monk, M. Boente, and J. Walker Phase III trial of every-3-weeks paclitaxel vs dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712) Int J Gynecol Cancer 23 8 Suppl. 1 2013 9 10
23. K. Bertelsen, A. Jakobsen, J. Stroyer, K. Nielsen, E. Sandberg, and J.E. Andersen A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish ovarian study group trial (DACOVA) Gynecol Oncol 49 1 1993 30 36
24. T.B. Hakes, E. Chalas, W.J. Hoskins, W.B. Jones, M. Markman, and S.C. Rubin Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma Gynecol Oncol 45 3 1992 284 289
25. 2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest oncology group and gynecologic oncology group phase 3 trial Gynecol Oncol 114 2 2009 195 198
26. Y. Takei, M. Suzuki, M. Ohwada, Y. Saga, T. Kohno, and S. Machida A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer Oncol Rep 10 4 2003 951 955
27. A. Khrunin, F. Ivanova, A. Moisseev, D. Khokhrin, Y. Sleptsova, and V. Gorbunova Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins Pharmacogenomics 13 2 2012 171 178
28. L. Norton A Gompertzian model of human breast cancer growth Cancer Res 48 24 Pt 1 1988 7067 7071
29. L. Norton, R. Simon, H.D. Brereton, and A.E. Bogden Predicting the course of gompertzian growth Nature 264 5586 1976 542 545
30. L. Levin, B. Lund, and A.P. Heintz Advanced ovarian cancer. An overview of multi-variate analyses of prognostic variables with special reference to the role of cytoreductive surgery Ann Oncol 4 Suppl. 4 1993 23 29
31. D. Lau, L. Guo, D. Gandara, L.J. Young, and L. Xue Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? Anticancer Drugs 15 9 2004 871 875
32. C.L. Chang, Y.T. Hsu, C.C. Wu, Y.Z. Lai, C. Wang, and Y.C. Yang Dose-dense chemotherapy improves mechanisms of antitumor immune response Cancer Res 73 1 2013 119 127
33. W.J. Lesterhuis, C.J. Punt, S.V. Hato, D. Eleveld-Trancikova, B.J. Jansen, and S. Nierkens Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice J Clin Invest 121 8 2011 3100 3108